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SExpression of dual-specificity tyrosine-(Y)-phosphorylation–
regulated kinase 2 (DYRK2) can be a favorable prognostic marker
in pulmonary adenocarcinoma
Shin-ichi Yamashita, MD, Masao Chujo, MD, Keita Tokuishi, MD, Kentaro Anami, MD,
Michiyo Miyawaki, MD, Satoshi Yamamoto, MD, and Katsunobu Kawahara, MD
Objectives: We investigated the possibility of DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation–regu-
lated kinase gene, to predict survival for patients with pulmonary adenocarcinoma.
Patients and Methods: One hundred forty-four patients with pulmonary adenocarcinoma underwent surgery in
our institute from 2000 to 2008. We used immunohistochemical analysis and real-time reverse-transcriptase poly-
merase chain reaction to determine the expression ofDYRK2 and compared this with the clinicopathologic factors
and survival.
Results: We found no correlation between DYRK2 expression by immunohistochemical and clinicopathologic
factors; however, a negative nodal status and negative lymphatic invasion were significantly associated with
DYRK2 expression by reverse-transcriptase polymerase chain reaction. Five-year disease-free survival in the
DYRK2-positive group (75.4%) was significantly different from that in the negative group (55.4%; P ¼ .03)
by immunohistochemical analysis. The 5-year overall survival of 89.2% in theDYRK2-positive group was better
than the 66.3% survival of the DYRK2-negative group (P ¼ .01). Quantitative real-time reverse-transcriptase
polymerase chain reaction analyses showed a significant difference between positive and negative expressions
for disease-free survival (P¼ .003) and overall survival (P¼ .007). In multivariate Cox regression analysis, neg-
ative DYRK2 protein and messenger RNA expression showed a worse prognostic value of survival (hazard ratio
[HR]¼ 4.7, 95% confidence intervals [CI]¼ 1.5–14.5, P¼.007; HR¼ 2.5, 95% CI¼ 1.1–6.1, P¼ .04, respec-
tively). When we analyzed adenocarcinoma cases except for bronchioloalveolar carcinoma, we found a close
correlation between DYRK2 expression by immunohistochemical analysis and nodal status (P ¼ .03). Further-
more, disease-free survivals between positive and negative groups of DYRK2 expression by immunohistochem-
istry (P¼ .03) and reverse-transcriptase polymerase chain reaction (P¼ .02) without bronchioloalveolar carcinoma
were significantly different. Overall survivals in both groups showed significant differences by immunohistochem-
istry (P ¼ .02) but not by reverse-transcriptase polymerase chain reaction (P ¼ .08).
Conclusions: These data showed that DYRK2 expression is associated with a favorable prognosis. (J Thorac
Cardiovasc Surg 2009;138:1303-8)
Yamashita et al General Thoracic SurgerySeveral clinical prognostic markers for lung cancer have
been recognized to dichotomize the risk, such as age, sex,
tumor stage, cellular differentiation, and vascular invasion.1
Furthermore, several molecular markers have been reported,
such as epidermal growth factor receptor,2 a cell growth
marker; p53,3 an apoptosis-related marker; and vascular
endothelial growth factor,4 an angiogenesis-related marker.
However, the clinical impact of these markers remains con-
troversial and unclear.
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regulated kinase gene, was identified as the most frequently
amplified and overexpressed gene in lung adenocarcinoma.5
It was also previously reported that DYRK2 regulates p53 to
induce apoptosis in response to DNA damage via the phos-
phorylation of Ser 456; however, the functional significance
of DYRK2 has not been reported and remains unclear. Re-
cently, we identified the potential of DYRK2 as a predictor
of chemotherapy benefit in non–small cell lung carcinoma
(Anticancer Research, in press), and we found that bron-
chioloalveolar carcinoma (BAC), which shows better prog-
nosis than the other adenocarcinoma subtypes, expressed
a high amount of this protein.




One hundred forty-four samples from patients treated surgically for lung
adenocarcinoma were obtained at Oita University Hospital (Oita, Japan)ardiovascular Surgery c Volume 138, Number 6 1303




BAC ¼ bronchioloalveolar carcinoma
CI ¼ confidence interval
HR ¼ hazard ratio
IHC ¼ immunohistochemistry
(immunohistochemical)
mRNA ¼ messenger RNA
PCR ¼ polymerase chain reaction
RT-PCR ¼ reverse-transcriptase polymerase chain
reaction
between 2000 and 2008. The study was approved by the Institutional Re-
viewBoard of Oita University Hospital, and all patients completed informed
consent forms. The samples were histologically diagnosed for primary ad-
enocarcinoma of the lung by hematoxylin and eosin staining. None of the
patients had received radiation therapy or chemotherapy before the opera-
tion. Adjacent normal lung tissue was also taken from all patients. Tissue
specimens were frozen immediately with RNAlater (QIAGEN, Tokyo,
Japan) and stored at80 C until RNA extraction. RNA from tissue samples
was prepared with an RNeasy Mini Kit (QIAGEN).
Immunohistochemical (IHC) Analysis
Four-micrometer sections were prepared for tissue slides. Antigen was
retrieved at 121 C for 10 minutes in an autoclave with citrate buffer (pH
6.0) after deparaffinization. Ten percent goat serum (Nichirei, Tokyo,
Japan) was used to block nonspecific binding. Staining with polyclonal
anti-DYRK2 antibody (AP7534a; Abgent, San Diego, Calif) with diluents,
1:50, was performed overnight at 4 C. After a reaction with 3% hydrogen
peroxide for 20 minutes at room temperature, polymer antirabbit (goat) an-
tibody (K4002; Dako, Glostrup, Denmark) for DYRK2 was applied and
incubated for 30 minutes at room temperature. Negative controls were
incubated without the primary antibody.
IHC staining was evaluated as follows: 0, no staining or faint cytoplas-
mic staining in less than 10% of tumor cells; 1þ, faint cytoplasmic staining
in more than 10% of tumor cells; 2þ, weak or moderate cytoplasmic staining
in more than 10% of tumor cells; 3þ, more than 10% of strong cytoplasmic
staining. Since the DYRK2 IHC staining study has not been reported previ-
ously, 0 or 1þstaining intensity was considered DYRK2 negative and 2þor
3þstaining was considered positive according to a previous report referring
to human epidermal growth receptor-2 protein.7 For evaluation reliability,
two independent assessors estimated the staining positivity of two serial
sections.
Quantitative Polymerase Chain Reaction (PCR)
Analysis
For quantitative evaluation of the RNA expression by PCR, we used
Taqman PCRmethods (TaqMan Gene Expression Assays; Applied Biosys-
tems, Tokyo, Japan) as previously reported.8 The DYRK2 gene was ampli-
fied by the following primer set: forward: gccatgttaaccaggaaacc, reverse:
gaagcctgaagctgacgaac.
The DYRK2 gene internal probe was the universal probe library probe
No. 70 (Roche, Mannheim, Germany). The PCR amplification condition
was 1 cycle at 50 C for 2 minutes and 95 C for 10 minutes followed by
50 cycles at 95 C for 15 seconds and 60 C for 1 minute. The measured
value was calculated by comparative threshold cycle methods8 and glycer-
aldehyde-3-phosphate dehydrogenase gene amplification was used as a con-
trol. All reactions were duplicated. The amounts ofDYRK2messenger RNA
(mRNA) were expressed as n-fold glyceraldehyde-3-phosphate dehydroge-
nasemRNA and the levels were compared relative to the normal lung tissues1304 The Journal of Thoracic and Cardiovascular Spool. A cutoff value of DYRK2 mRNA expression greater than 2.7, which
was the value of normal sample pool, was identified as a positive expression
and lower as a negative expression.
Statistical Analysis
All statistical analysis was performed with Stat View J5.0 (SAS Insti-
tute, Inc, Tokyo, Japan). The different variables of the tumors and normal
tissues were analyzed with c2 tests or Fisher’s exact tests. Time to progres-




Characteristics and DYRK2 Expression
We investigated the relationship between the clinico-
pathologic characteristics of adenocarcinoma and DYRK2
expression. As shown in Table 1, we found no correlation
betweenDYRK2 expression by IHC and any clinical factors;
however, DYRK2 mRNA expression in node-negative or
negative lymphatic invasion was significantly higher than
in node-positive or positive lymphatic invasion by reverse-
transcriptase polymerase chain reaction (RT-PCR). The ex-
pression pattern of DYRK2 is shown in Figure 1. Positive
cases showed strong granular staining in the cytoplasm of
cancer cells from the resected specimen of lung adenocarci-
noma (Figure 1).
Prognostic Values of DYRK2
Figure 2 shows disease-free survival and overall survival
according to the stratification of DYRK2 expression. Five-
year disease-free survival in the DYRK2-positive group
(75.4%) was significantly different from that in the negative
group (55.4%; P ¼ .03, Figure 2, A) by IHC. The 5-year
overall survival was 89.2% in the DYRK2-positive group
as compared with 66.3% in the DYRK2-negative group
(P ¼ .01, Figure 2, B). Quantitative real-time RT-PCR anal-
yses showed a significant difference between positive ex-
pression and negative for disease-free survival (Figure 2,
C; P ¼ .003) and overall survival (Figure 2, D; P ¼ .007).
In multivariate Cox regression analysis, negative DYRK2
protein expression indicated a worse prognosis of survival
(hazard ratio [HR] ¼ 4.7, 95% confidence interval [CI] ¼
1.5–14.5; P ¼ .007, Table 2), in addition to tumor size. Fur-
thermore, the potential of a prognostic factor by mRNA
expression of DYRK2 was elucidated by multivariate Cox
regression analysis (Table 3). Negative DYRK2 expression
showed a significantly higher hazard ratio (HR ¼ 2.5,
95% CI ¼ 1.1–6.1; P ¼ .04), the same as tumor size.
When we analyzed adenocarcinoma cases except the
BAC, we found the close correlation between DYRK2
expression by IHC and nodal status (P ¼ .03), but no corre-
lation between them by RT-PCR (p¼ .07). Furthermore, we
found that disease-free survivals between the positive and
negative groups of DYRK2 expression by IHC and RT-
PCR without BAC were significantly different (Figure 3,urgery c December 2009
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SA and C). Overall survivals in both groups showed signifi-
cant differences by IHC (Figure 3, B), but not by RT-PCR
(Figure 3, D). Taken together, adenocarcinoma expressing
DYRK2 showed better prognosis, and this protein can be
a favorable prognostic marker despite excluding BAC.















<70 80 35 (44) .57 49 (61) .12
70 64 25 (39) 31 (48)
Sex
Male 70 28 (40) .69 35 (50) .19
Female 74 32 (43) 45 (61)
Histologic subtype
Ad 102 43 (42) .85 50 (49) .01
BAC 42 17 (40) 30 (71)
Tumor size
<30 92 37 (40) .06 55 (60) .17
30 52 22 (52) 25 (60)
Nodal status
Positive 112 51 (46) .08 69 (62) .006
Negative 32 9 (28) 11 (34)
Vascular invasion
Positive 102 46 (45) .19 61 (60) .11
Negative 42 14 (33) 19 (45)
Lymphatic invasion
Positive 104 45 (43) .52 64 (62) .02
Negative 40 15 (38) 16 (40)
Stage .43 .1
IA 72 32 (44) 47 (64)
IB 27 13 (48) 14 (52)
IIA 5 1 (20) 0 (0)
IIB 6 1 (17) 2 (33)
IIIA 16 4 (25) 8 (50)
IIIB 13 7 (54) 6 (46)
IV 4 2 (50) 3 (75)
IHC, Immunohistochemistry; RT-PCR, reverse-transcriptase polymerase chain reac-
tion; Ad, adenocarcinoma; BAC, bronchioloalveolar carcinoma.The Journal of Thoracic and CDISCUSSION
In this study, we focused on the assessment of DYRK2 as
new prognostic markers of lung adenocarcinoma. DYRK2 is
a dual-specificity tyrosine-(Y)-phosphorylation- regulated
kinase gene, which has the potential to phosphorylate both
Ser/Thr and Tyr.5,9 DYRK families are involved in regulat-
ing processes such as cell proliferation, cytokinesis, and
cell differentiation. Furthermore, it is known that DYRK2
is an effector kinase for Ser46 of p53, which leads to apopto-
sis in the response to severe DNA damage.6 As the knock
down of theDYRK2 function attenuates doxorubicin (Adria-
mycin)-induced apoptosis, DYRK2 has a key role in p53-in-
duced apoptosis. In addition, DYRK2 can induce apoptosis
in a p53-independent manner.6 When we investigated the
relationship betweenDYRK2 expression and p53 expression
by IHC, the p53 positivity was quite low (37.5%, 15/40
cases) and no relationships existed between p53 and
DYRK2 expression (Anticancer Research, in press). There-
fore, we did not check p53 expression in this study, and
DYRK2 may exert independent manner of p53 function.
Further, we failed to show the correlation between DYRK2
expression and phosphor-p53 by anit-phospho-p53 (S46)
antibody, because DYRK2 functions in response to the
DNA damaging stimuli.
DYRK2 is overexpressed and amplified in lung adenocar-
cinoma and esophageal carcinomas5; however, the role of
DYRK2 in lung adenocarcinoma remains unclear. We found
that DYRK2 expression was associated with a better progno-
sis in lung adenocarcinoma. Additionally, the relationship
between node positivity and DYRK2 expression was con-
versely related; therefore, patients with DYRK2-positive tu-
mors might show better prognosis than those with negative
tumors. As previously reported,9 DYRK2 is associated
with cell cycle regulation, proliferation, and differentiation.
Our results may support these functions in lung adenocarci-
noma. In the present study, we found 40.6% ofDYRK2-pos-
itive cases by IHC and 56.1% by RT-PCR, higher than in
previous reports.5 These differences might be due to the
staining methods, use of a different antibody, or theFIGURE 1. Representative DYRK2 protein expression in adenocarcinoma and bronchioloalveolar carcinoma by immunohistochemistry. Cytoplasm of
cancer cells was stained strongly in 3þcases (4003).ardiovascular Surgery c Volume 138, Number 6 1305
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Sevaluation of IHC and sensitivity of RT-PCR. We could not
deny the overestimation owing to the possibility of artifacts.
Since the concordance rate between IHC positivity and
mRNA overexpression by real-time RT-PCR was 62.5%,
posttranscriptional modification of this gene expression
may exist. Inasmuch as both mRNA and protein expression
study showed a significant correlation between DYRK2 and
prognosis in lung adenocarcinoma, our result may be more
plausible than previous reports.
Although DYRK2 is not expressed in normal lung epithe-
lium and advanced acinar or papillary adenocarcinoma cells,
BAC, which arose from type II alveolar cells,10 and adeno-
carcinoma with a BAC component expressed higher levels
of DYRK2, but the difference was not significant. Inasmuch
as BAC possesses relatively favorable behavior,11 a positive
DYRK2 expression might lead to a better prognosis than
negative expression. Not only the BAC subtype but also
FIGURE 2. Disease-free survival (A) and overall survival (B) according to DYRK2 protein expression. Five-year disease-free survival is 75.4% in DYRK2-
positive group and 55.4% in negative (P¼ .03). Five-year overall survival is 85.4% inDYRK2-positive group and 68.5% in negative (P¼ .01). These are all
statistically significant. Disease-free survival (C) and overall survival (D) according toDYRK2mRNA expression. Five-year disease-free survival is 75.4% in
DYRK2-positive group and 55.4% in negative (P ¼ .003). Five-year overall survival is 89.2% in DYRK2-positive group and 66.3% in negative (P ¼ .007).
These are all statistically significant.
TABLE 2. Multivariate Cox proportional hazard model
Characteristics HR 95% CI P value
Histologic subtype (BAC vs Ad) 3.6 0.4-30.7 .23
Tumor size (<30 mm vs 30 mm) 3.1 1.2-7.9 .02
Nodal status (negative vs positive) 1.6 0.6-4.5 .36
Vascular invasion (negative vs positive) 1.3 0.5-3.3 .55
Lymphatic invasion (negative vs positive) 2.2 0.7-6.9 .16
DYRK2 expression (IHC) (positive vs negative) 4.7 1.5-14.5 .007
HR, Hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma; Ad,
adenocarcinoma; IHC, immunohistochemistry.
TABLE 3. Multivariate Cox proportional hazard model
Characteristics HR 95% CI P value
Histologic subtype (BAC vs Ad) 3.9 0.5-31.8 .2
Tumor size (<30 mm vs 30 mm) 2.6 1.1-6.4 .03
Nodal status (negative vs positive) 1.9 0.7-5.2 .22
Vascular invasion (negative vs positive) 1.3 0.5-3.3 .56
Lymphatic invasion (negative vs positive) 1.6 0.5-4.6 .41
DYRK2 expression (RT-PCR) (positive vs
negative)
2.5 1.1-6.1 .04
HR, Hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma; Ad,
adenocarcinoma; RT-PCR, reverse transcription polymerase chain reaction.1306 The Journal of Thoracic and Cardiovascular Surgery c December 2009
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SDYRK2-positive adenocarcinoma showed a better progno-
sis. Taken together, DYRK2 itself contributes to a better
prognosis and might be related to the slow growth of tumor
cells. Although the understanding of DYRK2 expression in
BAC is unclear, it may play a critical role in the initiation
of carcinogenesis because of the negative expression in nor-
mal lung tissues and advanced adenocarcinoma. We re-
searched the function of DYRK2 in adenocarcinoma and
found that adenocarcinoma with a BAC component had
high expression levels of this protein or mRNA (not signif-
icant). These findings led to the speculation that DYRK2 is
related to early events in carcinogenesis and is a powerful
tool to distinguish BAC from adenocarcinoma. Furthermore,
the sequence from BAC to adenocarcinoma might be eluci-
dated by this molecule.
In conclusion, our study demonstrated that patients with
DYRK2-positive adenocarcinoma had a better prognosis
than patients with DYRK2-negative adenocarcinoma.
DYRK2 might therefore be a powerful tool to stratify favor-
able candidate groups in lung cancer patients. Further inves-
tigation of DYRK2 might offer new insight into this
possibility.
We appreciate the technical support of Ms Yoko Miyanari from
the Department of Surgery II, Oita University Faculty of Medicine.
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Discussion
Dr David M. Jablons (San Francisco, Calif). I have 3 ques-
tions. When you did RT-PCR, what statistical method did you
use to validate the cutoff, and how did you choose a cutoff for an
arbitrary positive or negative value of 2.7?
Dr Yamashita. I used the cutoff point by using the estimation of
normal samples, because I alwaysmeasured the expression ofDYRK21308 The Journal of Thoracic and Cardiovascular Sby using normal expression samples, messenger expression. The cut-
off point is 2.7, and more than 2.7 of DYRK2 expression is positive.
Dr Jablons. Did you do that by a training set and a validation?
Dr Yamashita. No. We have to do that.
Dr Jablons. Second, have you looked at patients with more ad-
vanced stage non–small cell lung cancer to see whether this gene
actually has any prognostic and/or even predictive value, especially
in relationship to alleged sensitivity to a platinum-based doublet
chemotherapy?
Dr Yamashita. These samples were obtained from stage I to
stage IIIA. I haven’t checked stage IV or more aggressive tumors.
Dr Jablons.Was this gene predictive in patients with stage IIIA
disease?
Dr Yamashita. Unfortunately, I estimated the expression of
IIIA in the small samples. However, in our analysis, tumor size
and the DYRK2 expression are prognostic factors. I think that
IIIA is more—no, I or II has a depressed expression of DYRK2.
Maybe IIIA or IV should be downregulated of DYRK2. I’m not
sure, so I have to check by staging.
Dr Jablons. One last question: You mentioned in the manu-
script that BAC tumors had a higher expression. Do you think
that your prognostic value is represented by the fact that you are
picking up more BAC tumors in the stage I patient population?
Dr Yamashita. Not yet. That is an important question. I will
check the DYRK2 expression in BAC. So I have to check the prog-
nosis according to the DYRK2 expression in BAC.urgery c December 2009
